Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VNDA 
Vanda Pharmaceuticals Inc (VNDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VNDA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.67
1 Year Target Price $12.67
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.85% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 281.71M USD | Price to earnings Ratio - | 1Y Target Price 12.67 |
Price to earnings Ratio - | 1Y Target Price 12.67 | ||
Volume (30-day avg) 3 | Beta 0.67 | 52 Weeks Range 3.81 - 6.37 | Updated Date 06/30/2025 |
52 Weeks Range 3.81 - 6.37 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -21.98% | Operating Margin (TTM) -81.99% |
Management Effectiveness
Return on Assets (TTM) -7.05% | Return on Equity (TTM) -8.39% |
Valuation
Trailing PE - | Forward PE 30.3 | Enterprise Value -47161504 | Price to Sales(TTM) 1.4 |
Enterprise Value -47161504 | Price to Sales(TTM) 1.4 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA 12.91 | Shares Outstanding 58934500 | Shares Floating 52339713 |
Shares Outstanding 58934500 | Shares Floating 52339713 | ||
Percent Insiders 7.16 | Percent Institutions 77.62 |
Analyst Ratings
Rating 2 | Target Price 12.67 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vanda Pharmaceuticals Inc
Company Overview
History and Background
Vanda Pharmaceuticals Inc. was founded in 2002. It is a biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs.
Core Business Areas
- Neurology: Focuses on developing and marketing treatments for neurological disorders.
- Psychiatry: Focuses on developing and marketing treatments for psychiatric disorders.
Leadership and Structure
Vanda is led by Mihael H. Polymeropoulos, M.D., as President and CEO. The company has a typical corporate structure with departments for R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Hetlioz (tasimelteon): Hetlioz is a melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). The competitors include off-label melatonin use and potentially other emerging therapies in the sleep disorder market. Vanda reports annual sales exceeding $200 million, although specific market share data is difficult to ascertain precisely due to varying diagnostic practices and off-label treatments.
- Fanapt (iloperidone): Fanapt is an atypical antipsychotic indicated for the treatment of schizophrenia. Key competitors include other atypical antipsychotics such as risperidone, olanzapine, and quetiapine. Vanda's reported revenue from Fanapt is approximately $100 million annually, although market share is small compared to other atypical antipsychotics on the market
- Tradipitant: Tradipitant is a NK-1 receptor antagonist. It is still in development for gastroparesis and chronic pruritus. No market share or revenue to report yet.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. Growth is driven by innovation, aging populations, and increasing prevalence of chronic diseases.
Positioning
Vanda Pharmaceuticals is a specialty pharmaceutical company focused on niche markets with unmet medical needs, giving it a targeted, albeit limited, scope. Its strength lies in its focus and expertise in specific disorders.
Total Addressable Market (TAM)
The TAM for N24HSWD and Schizophrenia is estimated to be multi-billion dollars globally. Vanda has a small piece of the market. Vanda is attempting to expand TAM by getting new indications for existing drugs.
Upturn SWOT Analysis
Strengths
- Specialized focus on niche markets
- Established products with recurring revenue
- Proprietary drug candidates in pipeline
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Smaller market capitalization compared to competitors
Opportunities
- Expansion into new indications for existing drugs
- Strategic partnerships and collaborations
- Acquisition of complementary assets
Threats
- Competition from larger pharmaceutical companies
- Patent expiration and generic entry
- Regulatory challenges and delays
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- ALNY
Competitive Landscape
Vanda faces competition from larger pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its focus on niche markets and specialized expertise.
Growth Trajectory and Initiatives
Historical Growth: Historical growth rates cannot be calculated without historical data
Future Projections: Future projections are not possible with the data provided. Analyst estimates required.
Recent Initiatives: Vanda has been focusing on expanding the label for Hetlioz and advancing its pipeline product, Tradipitant.
Summary
Vanda Pharmaceuticals is a niche biopharmaceutical company with established products and a developing pipeline. While they have recurring revenue from Hetlioz and Fanapt, they face challenges due to their small size and reliance on a limited number of products. Vanda needs to focus on expanding its product portfolio and successfully navigating the regulatory landscape. Competition from larger pharmaceutical companies is a constant threat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on limited information and publicly available data and is for informational purposes only and not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vanda Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2006-04-12 | Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 368 | Website https://www.vandapharma.com |
Full time employees 368 | Website https://www.vandapharma.com | ||
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.